menu

Targeting Oncogenic Drivers in NSCLC: Opportunities & Challenges

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Targeting Oncogenic Drivers in NSCLC: Opportunities & Challenges

close
Targeting Oncogenic Drivers in NSCLC: Opportunities & Challenges
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Sponsored by

  • Overview

    Targeted therapies for oncogenic mutations in non-small cell lung cancer have shown a lot of potential when it comes to tailoring systemic treatment strategies to more specific tumor types and mutations. But just like any other therapeutic approach, it’s not without its challenges.

    To learn more about how we can identify these oncogenic drivers in our patients and what we should keep in mind when using targeted therapies, Mario Nacinovich sits down Dr. Lyudmila Bazhenova, board-certified medical oncologist and Professor of Medicine at the University of California San Diego.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    Targeted therapies for oncogenic mutations in non-small cell lung cancer have shown a lot of potential when it comes to tailoring systemic treatment strategies to more specific tumor types and mutations. But just like any other therapeutic approach, it’s not without its challenges.

    To learn more about how we can identify these oncogenic drivers in our patients and what we should keep in mind when using targeted therapies, Mario Nacinovich sits down Dr. Lyudmila Bazhenova, board-certified medical oncologist and Professor of Medicine at the University of California San Diego.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 3/6/21